Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Income towards Parent Company (2016 - 2026)

Amphastar Pharmaceuticals has reported Income towards Parent Company over the past 13 years, most recently at $58.4 million for Q4 2025.

  • For Q4 2025, Income towards Parent Company rose 34.67% year-over-year to $58.4 million; the TTM value through Dec 2025 reached $132.1 million, down 20.2%, while the annual FY2025 figure was $132.1 million, 20.2% down from the prior year.
  • Income towards Parent Company for Q4 2025 was $58.4 million at Amphastar Pharmaceuticals, up from $17.3 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $58.4 million in Q4 2025 and troughed at -$145.2 million in Q4 2023.
  • A 5-year average of $14.4 million and a median of $25.9 million in 2023 define the central range for Income towards Parent Company.
  • Biggest five-year swings in Income towards Parent Company: skyrocketed 703.36% in 2021 and later crashed 494.19% in 2022.
  • Year by year, Income towards Parent Company stood at $23.7 million in 2021, then crashed by 494.19% to -$93.2 million in 2022, then crashed by 55.79% to -$145.2 million in 2023, then skyrocketed by 129.86% to $43.4 million in 2024, then skyrocketed by 34.67% to $58.4 million in 2025.
  • Business Quant data shows Income towards Parent Company for AMPH at $58.4 million in Q4 2025, $17.3 million in Q3 2025, and $31.0 million in Q2 2025.